Minimizing use of nonhuman primates to inform risk to fertility and of adverse pregnancy outcomes with pharmaceuticals - Christopher J. Bowman; Ann Baker; Diann L. Blanset; Kimberly C. Brannen; Gary J. Chellman; Brian Enright; Wendy Halpern; Bethany R. Hannas; Kazushige Maki; Fumito Mikashima; Shermaine Mitchell-Ryan; Eve Mylchreest; et al. (Regulatory Toxicology and Pharmacology, 2026)

The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain - Helen Prior; Laura Andrews; Annick Cauvin; Hsiaotzu Chien; David O. Clarke; Kaushik Datta; Maggie Dempster; Noel Dybdal; Wendy Freebern; Lolke de Haan; Danuta Herzyk; Adam Hey; et al. (Regulatory Toxicology and Pharmacology, 2023)

Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach - Hsiao-Tzu Chien; Helen Prior; Laura Andrews; Leon van Aerts; Annick Cauvin; David O. Clarke; Kaushik Datta; Maggie Dempster; Noel Dybdal; Wendy Freebern; Lolke de Haan; Danuta Herzyk; et al. (Regulatory Toxicology and Pharmacology, 2023)